FDA Renews Peripheral and CNS Drugs Advisory Committee

Regulatory affairs teams managing CNS pipeline submissions should note that FDA has filed a renewed charter for the Peripheral and Central Nervous System Drugs Advisory Committee, resetting the two-year termination clock and reaffirming the structural framework through which neurological drug candidates receive expert advisory review ahead of agency decisions.

The Committee operates under a broad statutory base that includes 21 U.S.C. §355 and is governed by 21 CFR Part 14 alongside the Federal Advisory Committee Act. Its mandate covers both marketed and investigational human drug products indicated for neurologic diseases, with scope extending to evaluation of FDA's own research program supporting regulatory decisions in this space. The charter is explicit that Committee recommendations are advisory only; FDA retains full regulatory decision-making authority.

Operationally, the Committee is structured around a core of at least six voting members including the Chair. Annual operating costs are estimated at $90,142, comprising approximately $51,384 in federal staff support (0.25 person years), $4,468 in member payments, and $6,504 in travel and reimbursable expenses. Meeting frequency is not fixed; FDA convenes the Committee as needed and is not obligated to hold a meeting in every calendar year, a variable cadence that regulatory leads should factor into submission planning and advisory meeting request timelines.

For teams with active IND or NDA filings in neurology, the charter renewal carries a direct procedural implication: the Committee's composition and operating rules are now locked for another two-year cycle, barring early termination or mid-term amendment. Submissions that may trigger an advisory committee review during this window will be evaluated under these terms. All meetings default to public sessions consistent with the Government in the Sunshine Act, with closed sessions permissible only under defined statutory grounds.

The charter's two-year termination clause means the next renewal action will fall due in late 2028, providing a defined horizon for regulatory planning across CNS programs currently in late-stage development.

Source: FDA via What's New: Drugs RSS Feed, 27 October 2026.